{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jagadeesh D"],"funding":["National Institute of Arthritis and Musculoskeletal and Skin Diseases","Patient Education and Research Fund","Seagen Inc","Anderson Cancer Center Core","Takeda Pharmaceutical Company Ltd","Cutaneous T-Cell Lymphoma","National Cancer Institute","Haas Family Foundation","NCI NIH HHS","Millennium Pharmaceuticals Inc"],"pagination":["864-873"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9526494"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(10)"],"pubmed_abstract":["<h4>Background</h4>The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV.<h4>Patients and methods</h4>We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients.<h4>Results</h4>Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 ("],"journal":["The oncologist"],"pubmed_title":["Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma."],"pmcid":["PMC9526494"],"funding_grant_id":["R21-CA74117","K24 CA 86815","P30 CA016672","SGN35-IST-002","SGN35-IST-030","K24 CA086815","P30 CA008748","CA16672-22","SGN35-IST-r001"],"pubmed_authors":["Horwitz S","Duvic M","Onsum M","Lisano J","Bartlett NL","Kim Y","Advani R","Jagadeesh D","Little M","Fenton K","Jacobsen E","Trepicchio W"],"additional_accession":[]},"is_claimable":false,"name":"Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.","description":"<h4>Background</h4>The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV.<h4>Patients and methods</h4>We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients.<h4>Results</h4>Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 (","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-07-14T17:10:49.242Z","creation":"2025-04-05T17:26:06.51Z"},"accession":"S-EPMC9526494","cross_references":{"pubmed":["35948003"],"doi":["10.1093/oncolo/oyac137"]}}